HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antiplaque Comments

This article was originally published in The Rose Sheet

Executive Summary

New date for comments on advance notice of proposed rulemaking for OTC Antigingivitis/ Antiplaque Drug Products is Nov. 25, FDA announces. Reply comment period also has been extended to Feb. 23, 2004, agency says in Federal Register notice slated to appear Aug. 25. CHPA, CTFA jointly requested the extension in a July 15 petition (1"The Rose Sheet" July 28, 2003, In Brief). Groups wanted extra time to review data on ingredients the agency has proposed classifying as Category III (insufficient data) rather than Category I (safe and effective)...
Advertisement

Related Content

CTFA oral health care petition
Advertisement
UsernamePublicRestriction

Register

RS011451

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel